Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors

BackgroundLocal ablative treatments improve survival in patients with oligometastatic disease in addition to chemotherapy. The application of immune checkpoint inhibitors prolonged patients’ survival in different tumor entities. This raises the question if patients still benefit from intensified loc...

Full description

Bibliographic Details
Main Authors: Philipp Schubert, Sandra Rutzner, Markus Eckstein, Benjamin Frey, Claudia Schweizer, Marlen Haderlein, Sebastian Lettmaier, Sabine Semrau, Antoniu-Oreste Gostian, Jian-Guo Zhou, Udo S. Gaipl, Rainer Fietkau, Markus Hecht
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
radiotherapy
immunotherapy
immune checkpoint inhibitors
oligometastatic
single-lesion
all-lesion
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.576643/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.576643/full

Similar Items